Clinical Trial Search

Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG

Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05

Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0.0; 0.0; 1.5; 1.5 percentage of participants

Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants

Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants

Primary: Inhibition of Idiopathic Ventricular Tachycardia

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Change in Heart Rate — 17.0; 13.1 beats per minute

Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0; 0; 0; 0 Percentage of participants

Primary: Number of Participants With Successful Pulmonary Vein Isolation — 53 participants

Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Primary: Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery) — 46; 0 number of ventricular beats

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Primary Safety Endpoint - Percentage of Participants With Any PAE Within 7 Days — 4.7 Percentage of participants

Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants

Primary: Number of Participants With Primary Adverse Events (PAEs) — 0; 0; 0 Participants

Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants

Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants

Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants

Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events

Primary: Number of Participants With Device or Procedure-related Serious Adverse Events — 12; 2 Participants

Primary: Safety: Number of Participants With at Least One Primary Safety Event — 1; 1 Participants

Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001

Primary: Termination of SVT — 16; 21 participants

Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants

Primary: Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group — 2; 2; 9; 2…

Primary: Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing — 2; 9 Participants — p=0.008

Primary: Pivotal Main Phase Modified Intent-To-Treat (mITT) Analysis Set: Number of Participants With Primary Adverse Events (PAEs) — 8 Participants

Primary: Number of Participants With Symptomatic Rhythm Detection up to 90 Days — 69; 11 Participants

Primary: Total Fluoroscopy Time — 18.3; 7.5 minutes